Principles of the activin receptor signaling pathway and its inhibition
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
This review captures the anabolic and stimulatory effects observed with inhibition of the transforming growth factor β superfamily in muscle, blood, and bone. New medicinal substances that rectify activin, myostatin, and growth differentiation factor 11 signaling give hope to the many whose lives are affected by deterioration of these tissues. The review first covers the origin, structure, and common pathway of activins, myostatin, and growth differentiation factor 11 along with the pharmacodynamics of the new class of molecules designed to oppose the activin receptor signaling pathway. Current terminology surrounding this new class of molecules is inconsistent and does not infer functionality. Adopting inhibitors of the activin receptor signaling pathway (IASPs) as a generic term is proposed because it encapsulates the molecular mechanisms along the pathway trajectory. To conclude, a pragmatic classification of IASPs is presented that integrates functionality and side effects based on the data available from animals and humans. This provides researchers and clinicians with a tool to tailor IASPs therapy according to the need of projects or patients and with respect to side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afz046 · Cited by 3,803
Bisphosphonates: Mechanism of action and role in clinical practice
Drake, M. T., Clarke, B. L., & Khosla, S. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.9.1032 · Cited by 1,644
A deletion in the bovine myostatin gene causes the double–muscled phenotype in cattle
Grobet, L., Royo Martin, L. J., Poncelet, D., Pirottin, D., Brouwers, B., Riquet, J., Schoeberlein, A., Dunner, S., Ménissier, F., Massabanda, J., et al. (1997) · Nature Genetics · doi:10.1038/ng0997-71 · Cited by 1,556
Myostatin Mutation Associated with Gross Muscle Hypertrophy in a Child
Schuelke, M., Wagner, K. R., Stolz, L. E., Hübner, C., Riebel, T., Kömen, W., Braun, T., Tobin, J. F., & Lee, S.-J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040933 · Cited by 1,399
Vascular and Neurogenic Rejuvenation of the Aging Mouse Brain by Young Systemic Factors
Katsimpardi, L., Litterman, N. K., Schein, P. A., Miller, C. M., Loffredo, F. S., Wojtkiewicz, G. R., Chen, J. W., Lee, R. T., Wagers, A. J., & Rubin, L. L. (2014) · Science · doi:10.1126/science.1251141 · Cited by 1,037
Myostatin, a Negative Regulator of Muscle Growth, Functions by Inhibiting Myoblast Proliferation
Thomas, M., Langley, B., Berry, C., Sharma, M., Kirk, S., Bass, J., & Kambadur, R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004356200 · Cited by 1,014
Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women
Iannuzzi-Sucich, M., Prestwood, K. M., & Kenny, A. M. (2002) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/57.12.m772 · Cited by 890
Functional improvement of dystrophic muscle by myostatin blockade
Bogdanovich, S., Krag, T. O. B., Barton, E. R., Morris, L. D., Whittemore, L.-A., Ahima, R. S., & Khurana, T. S. (2002) · Nature · doi:10.1038/nature01154 · Cited by 831
Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size
Trendelenburg, A. U., Meyer, A., Rohner, D., Boyle, J., Hatakeyama, S., & Glass, D. J. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00105.2009 · Cited by 792
Research works printed but not linked: 145
- Kamiya, 2017, Sarcopenia: prevalence and prognostic implications in elderly patients with cardiovascular disease, JCSM Clin. Reports, 2, 1, 10.17987/jcsm-cr.v2i2.41 · DOI
- Trierweiler, 2018, Sarcopenia: A chronic complication of type 2 diabetes mellitus, Diabetol. Metab. Syndr., 10, 25, 10.1186/s13098-018-0326-5 · DOI · Paper page
- De Souza, 2017, Sarcopenia in patients with chronic kidney disease not yet on dialysis: analysis of the prevalence and associated factors, PLoS One, 12, 10.1371/journal.pone.0176230 · DOI · Paper page
- Benz, 2019, Sarcopenia in COPD: a systematic review and meta-analysis, Eur. Respir. Rev., 28, 10.1183/16000617.0049-2019 · DOI · Paper page
- Colón, 2018, Muscle and bone mass loss in the elderly population: advances in diagnosis and treatment, J. Biomed. Syd. (Syd), 3, 40
- Tsekoura, 2017, Sarcopenia and its impact on quality of life, 213, 10.1007/978-3-319-57379-3_19 · DOI · Paper page
- McDonald, 1991, New protein fold revealed by a 2.3-Å resolution crystal structure of nerve growth factor, Nature, 354, 411, 10.1038/354411a0 · DOI · Paper page
- Cash, 2009, The structure of myostatin:follistatin 288: insights into receptor utilization and heparin binding, EMBO J., 28, 2662, 10.1038/emboj.2009.205 · DOI · Paper page
- Gray, 1990, Requirement for activin a and transforming growth factor-β1 pro-regions in homodimer assembly, Science (80-.), 247, 1328, 10.1126/science.2315700 · DOI · Paper page
- Takahashi, 1995, Localization of furin to the trans-Golgi network and recycling from the cell surface involves Ser and Tyr residues within the cytoplasmic domain, J. Biol. Chem., 270, 28397, 10.1074/jbc.270.47.28397 · DOI
- Le, 2018, Tolloid cleavage activates latent GDF8 by priming the pro‐complex for dissociation, EMBO J., 37, 384, 10.15252/embj.201797931 · DOI
- Mi, 2015, Structure of bone morphogenetic protein 9 procomplex, Proc. Natl. Acad. Sci. U. S. A., 112, 3710, 10.1073/pnas.1501303112 · DOI · Paper page
- Wolfman, 2003, Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases, Proc. Natl. Acad. Sci. U. S. A., 100, 15842, 10.1073/pnas.2534946100 · DOI · Paper page
- Ling, 1986, Pituitary FSH is released by a heterodimer of the beta-subunits from the two forms of inhibin, Nature, 321, 779, 10.1038/321779a0 · DOI · Paper page
- Lewis, 2000, Betaglycan binds inhibin and can mediate functional antagonism of activin signalling, Nature, 404, 411, 10.1038/35006129 · DOI · Paper page
- Gold, 2009, Activin C antagonizes activin A in vitro and overexpression leads to pathologies in vivo, Am. J. Pathol., 174, 184, 10.2353/ajpath.2009.080296 · DOI
- McPherron, 1997, Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member, Nature, 387, 83, 10.1038/387083a0 · DOI · Paper page
- Nakashima, 1999, Expression of growth/differentiation factor 11, a new member of the BMP/TGFbeta superfamily during mouse embryogenesis, Mech. Dev., 80, 185, 10.1016/S0925-4773(98)00205-6 · DOI · Paper page
- Suragani, 2014, Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis, Nat. Med., 20, 408, 10.1038/nm.3512 · DOI · Paper page
- Walker, 2017, Structural basis for potency differences between GDF8 and GDF11, BMC Biol., 15, 19, 10.1186/s12915-017-0350-1 · DOI · Paper page
- Pepinsky, 2017, A prodomain fragment from the proteolytic activation of growth differentiation factor 11 remains associated with the mature growth factor and keeps it soluble, Biochemistry, 56, 4405, 10.1021/acs.biochem.7b00302 · DOI
- Walker, 2018, Molecular characterization of latent GDF8 reveals mechanisms of activation, Proc. Natl. Acad. Sci. U. S. A., 115, E866, 10.1073/pnas.1714622115 · DOI
- Schafer, 2016, Quantification of GDF11 and myostatin in human aging and cardiovascular disease, Cell Metab., 23, 10.1016/j.cmet.2016.05.023 · DOI · Paper page
- Lakshman, 2009, Measurement of myostatin concentrations in human serum: circulating concentrations in young and older men and effects of testosterone administration, Mol. Cell. Endocrinol., 302, 26, 10.1016/j.mce.2008.12.019 · DOI
- Sugino, 1988, Identification of a specific receptor for erythroid differentiation factor on follicular granulosa cell, J. Biol. Chem., 263, 15249, 10.1016/S0021-9258(19)37578-7 · DOI
- Lebrun, 1997, Activin and inhibin have antagonistic effects on ligand-dependent heteromerization of the type I and type II activin receptors and human erythroid differentiation, Mol. Cell. Biol., 17, 1682, 10.1128/MCB.17.3.1682 · DOI · Paper page
- Luo, 1997, Positive and negative regulation of type II TGF-beta receptor signal transduction by autophosphorylation on multiple serine residues, EMBO J., 16, 1970, 10.1093/emboj/16.8.1970 · DOI
- Andersson, 2006, Growth differentiation factor 11 signals through the transforming growth factor-β receptor ALK5 to regionalize the anterior-posterior axis, EMBO Rep., 7, 831, 10.1038/sj.embor.7400752 · DOI · Paper page
- Thompson, 2003, Structures of an ActRIIB:activin a complex reveal a novel binding mode for TGF-β ligand:receptor interactions, EMBO J., 22, 1555, 10.1093/emboj/cdg156 · DOI · Paper page
- Gray, 2000, Identification of a binding site on the type II activin receptor for activin and inhibin, J. Biol. Chem., 275, 3206, 10.1074/jbc.275.5.3206 · DOI
- Massague, 2005, Smad transcription factors, Genes Dev., 19, 2783, 10.1101/gad.1350705 · DOI · Paper page
- Loomans, 2016, Activin receptor-like kinases: a diverse family playing an important role in cancer, Am. J. Cancer Res., 6, 2431
- Bernard, 2006, Activin B can signal through both ALK4 and ALK7 in gonadotrope cells, Reprod. Biol. Endocrinol., 4, 52, 10.1186/1477-7827-4-52 · DOI · Paper page
- Tsuchida, 2004, Activin isoforms signal through type I receptor serine/threonine kinase ALK7, Mol. Cell. Endocrinol., 220, 59, 10.1016/j.mce.2004.03.009 · DOI
- Rebbapragada, 2003, Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis, Mol. Cell. Biol., 23, 7230, 10.1128/MCB.23.20.7230-7242.2003 · DOI · Paper page
- Attisano, 1996, Signal transduction by members of the transforming growth factor-beta superfamily, Cytokine Growth Factor Rev., 7, 327, 10.1016/S1359-6101(96)00042-1 · DOI
- Inman, 2002, SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7, Mol. Pharmacol., 62, 65, 10.1124/mol.62.1.65 · DOI · Paper page
- Herbertz, 2015, Clinical development of galunisertib (Ly2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway, Drug Des. Devel. Ther., 9, 4479
- Kidane, 2005, Recent advances in small molecule drug delivery, Curr. Opin. Chem. Biol., 9, 347, 10.1016/j.cbpa.2005.06.006 · DOI
- Fisher, 1996, Treatment of septic shock with the tumor necrosis factor receptor:fc fusion protein, N. Engl. J. Med., 334, 1697, 10.1056/NEJM199606273342603 · DOI · Paper page
- Pearsall, 2008, A soluble activin type IIA receptor induces bone formation and improves skeletal integrity, Proc. Natl. Acad. Sci. U. S. A., 105, 7082, 10.1073/pnas.0711263105 · DOI · Paper page
- Sherman, 2013, Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a Novel erythropoietic agent, in healthy postmenopausal women, J. Clin. Pharmacol., 53, 1121, 10.1002/jcph.160 · DOI
- Kanehisa, 2000, KEGG: Kyoto Encyclopedia of Genes and Genomes, Nucleic Acids Res., 28, 27, 10.1093/nar/28.1.27 · DOI · Paper page
- Chen, 2016, Pharmacokinetics and exposure-response of luspatercept in patients with beta-thalassemia: preliminary results from phase 2 studies, Blood, 128, 2463, 10.1182/blood.V128.22.2463.2463 · doi:10.1182/blood.v128.22.2463.2463
- Attie, 2014, A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers, Am. J. Hematol., 89, 766, 10.1002/ajh.23732 · DOI · Paper page
- Fenaux, 2020, Luspatercept in patients with lower-risk myelodysplastic syndromes, N. Engl. J. Med., 382, 140, 10.1056/NEJMoa1908892 · DOI · Paper page
- Mori-Yoshimura, 2019, Late phase II/III study of BYM338 in patients with sporadic inclusion body myositis (RESILIENT): japanese cohort data, Clin. Neurol., 59, 806
- Polkey, 2018, Activin type II receptor blockade for treatment of muscle depletion in COPD: a randomized trial, Am. J. Respir. Crit. Care Med.
- Pearsall, 2019, Follistatin-based ligand trap ACE-083 induces localized hypertrophy of skeletal muscle with functional improvement in models of neuromuscular disease, Sci. Rep., 9, 11392, 10.1038/s41598-019-47818-w · DOI
- Castonguay, 2019, Follistatin-288-Fc fusion protein promotes localized growth of skeletal muscle, J. Pharmacol. Exp. Ther., 368, 435, 10.1124/jpet.118.252304 · DOI
- Lerch, 2007, Structural and biophysical coupling of heparin and activin binding to follistatin isoform functions, J. Biol. Chem., 282, 15930, 10.1074/jbc.M700737200 · DOI · Paper page
- Statland, 2018, FSHD / OPMD / EDMD /. DMI: P.365: Results for a dose-escalation phase 2 study to evaluate ACE-083, a local muscle therapeutic, in patients with facioscapulohumeral muscular dystrophy, Neuromuscul. Disord., 28, S140, 10.1016/j.nmd.2018.06.413 · doi:10.1016/j.nmd.2018.06.413
- Shy, 2018, CMT AND NEUROGENIC DISEASE: P.339: preliminary phase 2 results for ACE-083, local muscle therapeutic, in patients with CMT1 and CMTX, Neuromuscul. Disord., 28, S132, 10.1016/j.nmd.2018.06.387 · doi:10.1016/j.nmd.2018.06.387
- Yaden, 2014, Follistatin: a novel therapeutic for the improvement of muscle regeneration, J. Pharmacol. Exp. Ther., 349, 355, 10.1124/jpet.113.211169 · DOI
- Lodberg, 2019, A follistatin-based molecule increases muscle and bone mass without affecting the red blood cell count in mice, FASEB J., 33, 6001, 10.1096/fj.201801969RR · DOI
- Wagner, 2008, A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy, Ann. Neurol., 63, 561, 10.1002/ana.21338 · DOI · Paper page
- Zhang, 2011, Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease, FASEB J., 25, 1653, 10.1096/fj.10-176917 · DOI · Paper page
- Bhattacharya, 2018, Safety, tolerability, pharmacokinetics, and pharmacodynamics of domagrozumab (PF-06252616), an antimyostatin monoclonal antibody, in healthy subjects, Clin. Pharmacol. Drug Dev., 7, 484, 10.1002/cpdd.386 · DOI · Paper page
- Kalra, 2019, P.126SRK-015, a fully human monoclonal antibody inhibiting myostatin activation, offers sustained target engagement across multiple species, including humans, Neuromuscul. Disord., 29, S85, 10.1016/j.nmd.2019.06.182 · doi:10.1016/j.nmd.2019.06.182
- Long, 2019, Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy, Hum. Mol. Genet., 28, 1076, 10.1093/hmg/ddy382 · DOI · Paper page
- Whittemore, 2003, Inhibition of myostatin in adult mice increases skeletal muscle mass and strength, Biochem. Biophys. Res. Commun., 300, 965, 10.1016/S0006-291X(02)02953-4 · DOI · Paper page
- Pistilli, 2011, Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy, Am. J. Pathol., 178, 1287, 10.1016/j.ajpath.2010.11.071 · DOI
- Alyodawi, 2019, Compression of morbidity in a progeroid mouse model through the attenuation of myostatin/activin signalling, J. Cachexia Sarcopenia Muscle, 10, 662, 10.1002/jcsm.12404 · DOI
- Sepulveda, 2015, Evaluation of follistatin as a therapeutic in models of skeletal muscle atrophy associated with denervation and tenotomy, Sci. Rep., 5, 17535, 10.1038/srep17535 · DOI
- Zhou, 2010, Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival, Cell, 142, 531, 10.1016/j.cell.2010.07.011 · DOI · Paper page
- Meier, 2020, Inhibition of the activin receptor signaling pathway: a novel intervention against osteosarcoma, Cancer Med., cam4.3581
- Yaffe, 1977, Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle, Nature, 270, 725, 10.1038/270725a0 · DOI · Paper page
- Lokireddy, 2011, Myostatin promotes the wasting of human myoblast cultures through promoting ubiquitin-proteasome pathway-mediated loss of sarcomeric proteins, Am. J. Physiol. - Cell Physiol., 301, C1316, 10.1152/ajpcell.00114.2011 · DOI · Paper page
- Welle, 2009, Stimulation of skeletal muscle myofibrillar protein synthesis, p70 S6 kinase phosphorylation, and ribosomal protein S6 phosphorylation by inhibition of myostatin in mature mice, Am. J. Physiol. - Endocrinol. Metab., 296, E567, 10.1152/ajpendo.90862.2008 · DOI · Paper page
- McFarlane, 2006, Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-κB-independent, FoxO1-dependent mechanism, J. Cell. Physiol., 209, 501, 10.1002/jcp.20757 · DOI · Paper page
- Yang, 2007, Myostatin induces cyclin D1 degradation to cause cell cycle arrest through a phosphatidylinositol 3-kinase/AKT/GSK-3β pathway and is antagonized by insulin-like growth factor, J. Biol. Chem., 282, 3799, 10.1074/jbc.M610185200 · DOI · Paper page
- Asfour, 2018, Myogenic regulatory factors: the orchestrators of myogenesis after 30 years of discovery, Exp. Biol. Med., 243, 118, 10.1177/1535370217749494 · DOI · Paper page
- Berkes, 2005, MyoD and the transcriptional control of myogenesis, Semin. Cell Dev. Biol., 16, 585, 10.1016/j.semcdb.2005.07.006 · DOI · Paper page
- Langley, 2002, Myostatin inhibits myoblast differentiation by down-regulating MyoD expression, J. Biol. Chem., 277, 49831, 10.1074/jbc.M204291200 · DOI · Paper page
- Vermeulen, 2003, The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer, Cell Prolif., 36, 131, 10.1046/j.1365-2184.2003.00266.x · DOI · Paper page
- Varshavsky, 2017, The ubiquitin system, autophagy, and regulated protein degradation, Annu. Rev. Biochem., 86, 123, 10.1146/annurev-biochem-061516-044859 · DOI · Paper page
- Foletta, 2011, The role and regulation of MAFbx/atrogin-1 and MuRFl in skeletal muscle atrophy, Pflugers Arch. Eur. J. Physiol., 461, 325, 10.1007/s00424-010-0919-9 · DOI · Paper page
- Polge, 2018, A muscle-specific MuRF1-E2 network requires stabilization of MuRF1-E2 complexes by telethonin, a newly identified substrate, J. Cachexia Sarcopenia Muscle, 9, 129, 10.1002/jcsm.12249 · DOI
- Lee, 2011, Myostatin induces autophagy in skeletal muscle in vitro, Biochem. Biophys. Res. Commun., 415, 632, 10.1016/j.bbrc.2011.10.124 · DOI
- Lee, 2012, Role of satellite cells versus myofibers in muscle hypertrophy induced by inhibition of the myostatin/activin signaling pathway, Proc. Natl. Acad. Sci. U. S. A., 109, 10.1073/pnas.1206410109 · DOI · Paper page
- Bachettini, 2020, Sarcopenia as a mortality predictor in community-dwelling older adults: a comparison of the diagnostic criteria of the European Working Group on Sarcopenia in Older People, Eur. J. Clin. Nutr., 74, 573, 10.1038/s41430-019-0508-8 · DOI
- Padhi, 2014, Pharmacological inhibition of myostatin and changes in lean body mass and lower extremity muscle size in patients receiving androgen deprivation therapy for prostate cancer, J. Clin. Endocrinol. Metab., 99, E1967, 10.1210/jc.2014-1271 · DOI · Paper page
- Woodhouse, 2016, STUDY INVESTIGATORS, a phase 2 randomized study investigating the efficacy and safety of myostatin antibody LY2495655 versus placebo in patients undergoing elective total hip arthroplasty, J. Frailty Aging, 5, 62
- Becker, 2015, Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial, Lancet Diabetes Endocrinol., 3, 948, 10.1016/S2213-8587(15)00298-3 · DOI · Paper page
- Schols, 1995, Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease: a placebo-controlled randomized trial, Am. J. Respir. Crit. Care Med., 152, 1268, 10.1164/ajrccm.152.4.7551381 · DOI · Paper page
- Casaburi, 2004, Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease, Am. J. Respir. Crit. Care Med., 170, 870, 10.1164/rccm.200305-617OC · DOI · Paper page
- Sharma, 2008, Anabolic steroids in COPD: a review and preliminary results of a randomized trial, Chron. Respir. Dis., 5, 169, 10.1177/1479972308092350 · DOI
- Glasser, 2018, Locally acting ACE-083 increases muscle volume in healthy volunteers, Muscle Nerve, 10.1002/mus.26113 · DOI · Paper page
- Ruckle, 2009, Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women, J. Bone Miner. Res., 24, 744, 10.1359/jbmr.081208 · DOI · Paper page
- Carrancio, 2014, An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin, Br. J. Haematol., 165, 870, 10.1111/bjh.12838 · DOI
- Valent, 2018, Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts, Haematologica, 103, 1593, 10.3324/haematol.2018.192518 · DOI
- Oikonomidou, 2018, What can we learn from ineffective erythropoiesis in thalassemia?, Blood Rev., 32, 130, 10.1016/j.blre.2017.10.001 · DOI
- Blank, 2015, TGF-β signaling in the control of hematopoietic stem cells, Blood, 125, 3542, 10.1182/blood-2014-12-618090 · DOI · Paper page
- Zhou, 2008, Inhibition of the TGF-β receptor I kinase promotes hematopoiesis in MDS, Blood, 112, 3434, 10.1182/blood-2008-02-139824 · DOI · Paper page
- Bhagat, 2013, MiR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling, Blood, 121, 2875, 10.1182/blood-2011-12-397067 · DOI · Paper page
- Yu, 1987, Importance of FSH-releasing protein and inhibin in erythrodifferentiation, Nature, 330, 765, 10.1038/330765a0 · DOI · Paper page
- Broxmeyer, 1988, Selective and indirect modulation of human multipotential and erythroid hematopoietic progenitor cell proliferation by recombinant human activin and inhibin, Proc. Natl. Acad. Sci. U. S. A., 85, 9052, 10.1073/pnas.85.23.9052 · DOI
- Shiozaki, 1998, Activin A: A commitment factor in erythroid differentiation, Biochem. Biophys. Res. Commun., 242, 631, 10.1006/bbrc.1997.8020 · DOI
- Guerra, 2019, Lack of Gdf11 does not improve anemia or prevent the activity of RAP-536 in a mouse model of beta-thalassemia, Blood, 10.1182/blood.2019001057 · DOI
- Goldstein, 2019, Steady-state and regenerative hematopoiesis occur normally in mice in the absence of GDF11, Blood, 10.1182/blood.2019002066 · DOI
- Langdon, 2015, RAP-011, an activin receptor ligand trap, increases hemoglobin concentration in Hepcidin transgenic mice, Am. J. Hematol., 90, 8, 10.1002/ajh.23856 · DOI
- Iancu-Rubin, 2013, Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap, Exp. Hematol., 41, 155, 10.1016/j.exphem.2012.12.002 · DOI
- Crosby, 1997, Guidelines for red blood cell and plasma transfusion for adults and children, CMAJ, 156, S1
- Van Der Putten, 2008, Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure, Nat. Clin. Pract. Nephrol., 4, 47, 10.1038/ncpneph0655 · DOI · Paper page
- Gilliss, 2011, Reducing noninfectious risks of blood transfusion, Anesthesiology, 115, 635, 10.1097/ALN.0b013e31822a22d9 · DOI · Paper page
- Lodberg, 2018, A soluble activin type IIA receptor mitigates the loss of femoral neck bone strength and cancellous bone mass in a mouse model of disuse osteopenia, Bone, 110, 326, 10.1016/j.bone.2018.02.026 · DOI
- Bonucci, 2012, Bone mineralization, Front. Biosci., 17, 100, 10.2741/3918 · DOI
- Long, 2012, Building strong bones: molecular regulation of the osteoblast lineage, Nat. Rev. Mol. Cell Biol., 13, 27, 10.1038/nrm3254 · DOI · Paper page
- Väänänen, 2008, Osteoclast lineage and function, Arch. Biochem. Biophys., 473, 132, 10.1016/j.abb.2008.03.037 · DOI · Paper page
- Eijken, 2007, The activin A-follistatin system: potent regulator of human extracellular matrix mineralization, FASEB J., 21, 2949, 10.1096/fj.07-8080com · DOI · Paper page
- Ikenoue, 1999, Inhibitory effects of activin-A on osteoblast differentiation during cultures of fetal rat calvarial cells, J. Cell. Biochem., 75, 206, 10.1002/(SICI)1097-4644(19991101)75:2<206::AID-JCB3>3.0.CO;2-T · DOI · Paper page
- Liu, 2016, GDF11 decreases bone mass by stimulating osteoclastogenesis and inhibiting osteoblast differentiation, Nat. Commun., 7, 12794, 10.1038/ncomms12794 · DOI · Paper page
- Sakai, 1993, Activin enhances osteoclast-like cell formation in vitro, Biochem. Biophys. Res. Commun., 195, 39, 10.1006/bbrc.1993.2006 · DOI
- Fuller, 2000, Activin A is an essential cofactor for osteoclast induction, Biochem. Biophys. Res. Commun., 268, 2, 10.1006/bbrc.2000.2075 · DOI
- Fowler, 2015, Activin A inhibits RANKL-mediated osteoclast formation, movement and function in murine bone marrow macrophage cultures, J. Cell. Sci., 128, 683
- Hamrick, 2003, Increased bone mineral density in the femora of GDF8 knockout mice, Anat. Rec., 272A, 388, 10.1002/ar.a.10044 · DOI · Paper page
- Hamrick, 2006, Increased muscle mass with myostatin deficiency improves gains in bone strength with exercise, J. Bone Miner. Res., 21, 477, 10.1359/JBMR.051203 · DOI · Paper page
- Lotinun, 2010, A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys, Bone, 46, 1082, 10.1016/j.bone.2010.01.370 · DOI
- Jerome, 1999, Effect of treatment for 6 months with human parathyroid hormone (1-34) peptide in ovariectomized cynomolgus monkeys (Macaca fascicularis), Bone, 25, 301, 10.1016/S8756-3282(99)00166-0 · DOI
- Doyle, 2018, Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption, Osteoporos. Int., 29, 685, 10.1007/s00198-017-4323-6 · DOI
- Brent, 2020, Activin type IIA decoy receptor and intermittent parathyroid hormone in combination overturns the bone loss in disuse-osteopenic mice, Bone, 142
- Abdulkadyrov, 2014, Sotatercept in patients with osteolytic lesions of multiple myeloma, Br. J. Haematol., 165, 814, 10.1111/bjh.12835 · DOI
- Tillet, 2015, Emerging roles of BMP9 and BMP10 in hereditary hemorrhagic telangiectasia, Front. Genet., 5, 456, 10.3389/fgene.2014.00456 · DOI
- Campbell, 2017, Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: results of a randomized, placebo-controlled clinical trial, Muscle Nerve, 55, 458, 10.1002/mus.25268 · DOI · Paper page
- Gregory, 2004, Regulation of gonadotropins by inhibin and activin, Semin. Reprod. Med., 22, 253, 10.1055/s-2004-831901 · DOI
- Raftopoulos, 2016, Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies, Support. Care Cancer, 24, 1517
- Braekkan, 2010, Hematocrit and risk of venous thromboembolism in a general population. The Tromso study, Haematologica, 95, 270, 10.3324/haematol.2009.008417 · DOI · Paper page
- Greenwald, 2003, The BMP7/ActRII extracellular domain complex provides new insights into the cooperative nature of receptor assembly, Mol. Cell, 11, 605, 10.1016/S1097-2765(03)00094-7 · DOI · Paper page
- Makanji, 2011, Generation of a specific activin antagonist by modification of the activin A propeptide, Endocrinology, 152, 3758, 10.1210/en.2011-1052 · DOI
- Aykul, 2017, Biochemical and cellular analysis reveals ligand binding specificities, a molecular basis for ligand recognition, and membrane association-dependent activities of cripto-1 and cryptic, J. Biol. Chem., 292, 4138, 10.1074/jbc.M116.747501 · DOI
- Souza, 2008, Proteomic identification and functional validation of activins and bone morphogenetic protein 11 as candidate novel muscle mass regulators, Mol. Endocrinol., 22, 2689, 10.1210/me.2008-0290 · DOI · Paper page
- Wu, 2010, Identification and analysis of type II TGF- receptors in BMP-9-induced osteogenic differentiation of C3H10T1/2 mesenchymal stem cells, Acta Biochim, Biophys. Sin. (Shanghai)., 42, 699, 10.1093/abbs/gmq075 · DOI
- Kienast, 2016, Rapid activation of bone morphogenic protein 9 by receptor-mediated displacement of pro-domains, J. Biol. Chem., 291, 3395, 10.1074/jbc.M115.680009 · DOI
- Townson, 2012, Specificity and structure of a high affinity ALK1 complex, J.Biol.Chem., 287, 27313, 10.1074/jbc.M112.377960 · DOI · Paper page
- Koncarevic, 2012, A novel therapeutic approach to treating obesity through modulation of TGFβ signaling, Endocrinology, 153, 3133, 10.1210/en.2012-1016 · DOI · Paper page
- Hashimoto, 2000, Difference between follistatin isoforms in the inhibition of activin signalling: activin neutralizing activity of follistatin isoforms is dependent on their affinity for activin, Cell. Signal., 12, 565, 10.1016/S0898-6568(00)00099-1 · DOI
- Smith, 2015, Myostatin neutralization results in preservation of muscle mass and strength in preclinical models of tumor-induced muscle wasting, Mol. Cancer Ther., 14, 1661, 10.1158/1535-7163.MCT-14-0681 · DOI · Paper page
- Pirruccello-Straub, 2018, Blocking extracellular activation of myostatin as a strategy for treating muscle wasting, Sci. Rep., 8, 2292, 10.1038/s41598-018-20524-9 · DOI · Paper page
- Dagbay, 2020, Structural basis for specific inhibition of extracellular activation of pro- or latent myostatin by the monoclonal antibody SRK-015, J. Biol. Chem., 10.1074/jbc.RA119.012293 · DOI
- Andre, 2017, Skelet. Muscle, 7, 25, 10.1186/s13395-017-0141-y · DOI · Paper page
- Komrokji, 2018, Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial, Lancet Haematol., 10.1016/S2352-3026(18)30002-4 · DOI
- Rooks, 2017, Effect of bimagrumab on thigh muscle volume and composition in men with casting-induced atrophy, J. Cachexia, Sarcopenia Muscle., 8, 727, 10.1002/jcsm.12205 · DOI · Paper page
- Hanna, 2019, Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial, Lancet Neurol., 18, 834, 10.1016/S1474-4422(19)30200-5 · DOI · Paper page
- Krivickas, 2009, Single muscle fiber contractile properties in adults with muscular dystrophy treated with MYO-029, Muscle Nerve, 39, 3, 10.1002/mus.21200 · DOI · Paper page
- Jameson, 2012, Safety of the antimyostatin monoclonal antibody LY2495655 in healthy subjects and patients with advanced cancer, J. Clin. Oncol., 30, 2516, 10.1200/jco.2012.30.15_suppl.2516 · DOI
Cited by
Wu, M., Wu, S., Chen, W., & Li, Y.-P. (2024) · Cell Research · doi:10.1038/s41422-023-00918-9 · Cited by 445
Stefanakis, K., Kokkorakis, M., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156057 · Cited by 142
Bone-muscle crosstalk under physiological and pathological conditions
Dong, Y., Yuan, H., Ma, G., & Cao, H. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05331-y · Cited by 52
“ActRIIB-Fc fusion protein which binds myostatin could increase osteogenesis indicated by elevated serum Type I procollagen and BMP without affecting muscles in mice, suggesting a direct effect of ActRIIB on OBs [96, 97].”
BackgroundEffect of Bimagrumab on Body Composition: A Systematic Review and Meta-Analysis
Kanbay, M., Siriopol, D., Copur, S., Hasbal, N. B., Güldan, M., Kalantar-Zadeh, K., Garfias-Veitl, T., & von Haehling, S. (2024) · Aging Clinical and Experimental Research · doi:10.1007/s40520-024-02825-4 · Cited by 45
“…mitogen-activated protein kinases (MAPK) activation, suppression of mothers against decapentaplegic (Smad) and forkhead box transcription factors (FoxO) activation and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapam-ycin (mTOR) pathway inhibition occur [28].”
Metadata
- Authors
- Lodberg, A.
- Venue
- Cytokine & Growth Factor Reviews
- Publisher
- Elsevier BV
- Published
- 2021-08
- Volume
- 60
- Pages
- 1-17
- ISSN
- 1359-6101 (ISSN-L)
- OpenAlex
- W3154035165
- Cited by
- 62
- References
- 39
- FWCI
- 0.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Funders
- Elsass Foundation
- Danish Lung Association
- Engineer Frode V Nyegaard and Wife's Foundation
- Novo Nordisk Foundation
- AP Moller Fonden
- Dagmar Marshall Fund
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Principles of the activin receptor signaling pathway and its inhibition. https://app.cochat.ai/papers/10.1016/j.cytogfr.2021.04.001
- The paper
- Lodberg, A. (2021). Principles of the activin receptor signaling pathway and its inhibition. Cytokine & Growth Factor Reviews. https://doi.org/10.1016/j.cytogfr.2021.04.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.